Immunoadsorption therapy and complement activation
Complement activation was studied in six patients treated with immunoadsorption columns Ig-ADSOPAK for myasthenia gravis. Mean therapy duration was 18.6 months (range 4–28 months). Prior and after each procedure, concentrations of C3 and C4 were examined, hemolytic activity of complement by a classi...
Gespeichert in:
| Veröffentlicht in: | Transfusion and apheresis science 2005-06, Vol.32 (3), p.263-267 |
|---|---|
| Hauptverfasser: | , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 267 |
|---|---|
| container_issue | 3 |
| container_start_page | 263 |
| container_title | Transfusion and apheresis science |
| container_volume | 32 |
| creator | Pták, J. Lochman, J. |
| description | Complement activation was studied in six patients treated with immunoadsorption columns Ig-ADSOPAK for myasthenia gravis. Mean therapy duration was 18.6 months (range 4–28 months). Prior and after each procedure, concentrations of C3 and C4 were examined, hemolytic activity of complement by a classic pathway (CH50) was determined, as well as terminal complement complex (TCC). After each immunoadsorption procedure, a decrease of C3 and C4 was noted (median 21.19% and 19.68%, respectively). The CH50 and TCC follow-up showed statistically significant complement activation. Median of TCC accrual was 60.21% and median of CH50 decrease was 23.24%. No clinical manifestations of complement activation were present. With increasing number of procedures a marked decrease of TCC activation was observed in five patients, which was statistically significant in three of them (
p
<
0.05). This finding may indicate an immunomodulating effect of long-term adsorption therapy. With increasing number of procedures, an inhibition in complement system reactivity occurs. This result, however, has to be confirmed on a larger group of patients. |
| doi_str_mv | 10.1016/j.transci.2004.07.014 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_67918766</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><els_id>S1473050205000480</els_id><sourcerecordid>67918766</sourcerecordid><originalsourceid>FETCH-LOGICAL-c363t-ecc31b476d6abfeb557b36787c4f294dffaffc0b0d101e96d9d5a7b37b0598223</originalsourceid><addsrcrecordid>eNqFkE1LxDAQhoMorq7-BGVP3lqTNk3ak8jix8KCFz2HNJlglrapSbqw_94sW_DoaebwvDO8D0J3BOcEE_a4y6OXQ1A2LzCmOeY5JvQMXZGa1xlhdXmedsrLDFe4WKDrEHYYE04adokWpGooJaS4QsWm76fBSR2cH6N1wyp-g5fjYSUHvVKuHzvoYYgrqaLdyyNxgy6M7ALcznOJvl5fPtfv2fbjbbN-3maqZGXMQKmStJQzzWRroK0q3paM11xRUzRUGyONUbjFOvWBhulGVzIhvMVVUxdFuUQPp7ujdz8ThCh6GxR0nRzATUEw3qSyjCWwOoHKuxA8GDF620t_EASLoyyxE7MscZQlMBdJVsrdzw-mtgf9l5rtJODpBECqubfgRToBgwJtPagotLP_vPgFVSl-qw</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>67918766</pqid></control><display><type>article</type><title>Immunoadsorption therapy and complement activation</title><source>MEDLINE</source><source>Elsevier ScienceDirect Journals</source><creator>Pták, J. ; Lochman, J.</creator><creatorcontrib>Pták, J. ; Lochman, J.</creatorcontrib><description>Complement activation was studied in six patients treated with immunoadsorption columns Ig-ADSOPAK for myasthenia gravis. Mean therapy duration was 18.6 months (range 4–28 months). Prior and after each procedure, concentrations of C3 and C4 were examined, hemolytic activity of complement by a classic pathway (CH50) was determined, as well as terminal complement complex (TCC). After each immunoadsorption procedure, a decrease of C3 and C4 was noted (median 21.19% and 19.68%, respectively). The CH50 and TCC follow-up showed statistically significant complement activation. Median of TCC accrual was 60.21% and median of CH50 decrease was 23.24%. No clinical manifestations of complement activation were present. With increasing number of procedures a marked decrease of TCC activation was observed in five patients, which was statistically significant in three of them (
p
<
0.05). This finding may indicate an immunomodulating effect of long-term adsorption therapy. With increasing number of procedures, an inhibition in complement system reactivity occurs. This result, however, has to be confirmed on a larger group of patients.</description><identifier>ISSN: 1473-0502</identifier><identifier>EISSN: 1878-1683</identifier><identifier>DOI: 10.1016/j.transci.2004.07.014</identifier><identifier>PMID: 15944112</identifier><language>eng</language><publisher>England: Elsevier Ltd</publisher><subject>Adult ; Aged ; Blood Component Removal ; Complement Activation ; Complement C3 - analysis ; Complement C4 - analysis ; Female ; Health technology assessment ; Humans ; Immunosorbent Techniques ; Male ; Middle Aged ; Myasthenia Gravis - blood ; Myasthenia Gravis - therapy</subject><ispartof>Transfusion and apheresis science, 2005-06, Vol.32 (3), p.263-267</ispartof><rights>2005 Elsevier Ltd</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c363t-ecc31b476d6abfeb557b36787c4f294dffaffc0b0d101e96d9d5a7b37b0598223</citedby><cites>FETCH-LOGICAL-c363t-ecc31b476d6abfeb557b36787c4f294dffaffc0b0d101e96d9d5a7b37b0598223</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktohtml>$$Uhttps://www.sciencedirect.com/science/article/pii/S1473050205000480$$EHTML$$P50$$Gelsevier$$H</linktohtml><link.rule.ids>314,776,780,3537,27901,27902,65306</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/15944112$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Pták, J.</creatorcontrib><creatorcontrib>Lochman, J.</creatorcontrib><title>Immunoadsorption therapy and complement activation</title><title>Transfusion and apheresis science</title><addtitle>Transfus Apher Sci</addtitle><description>Complement activation was studied in six patients treated with immunoadsorption columns Ig-ADSOPAK for myasthenia gravis. Mean therapy duration was 18.6 months (range 4–28 months). Prior and after each procedure, concentrations of C3 and C4 were examined, hemolytic activity of complement by a classic pathway (CH50) was determined, as well as terminal complement complex (TCC). After each immunoadsorption procedure, a decrease of C3 and C4 was noted (median 21.19% and 19.68%, respectively). The CH50 and TCC follow-up showed statistically significant complement activation. Median of TCC accrual was 60.21% and median of CH50 decrease was 23.24%. No clinical manifestations of complement activation were present. With increasing number of procedures a marked decrease of TCC activation was observed in five patients, which was statistically significant in three of them (
p
<
0.05). This finding may indicate an immunomodulating effect of long-term adsorption therapy. With increasing number of procedures, an inhibition in complement system reactivity occurs. This result, however, has to be confirmed on a larger group of patients.</description><subject>Adult</subject><subject>Aged</subject><subject>Blood Component Removal</subject><subject>Complement Activation</subject><subject>Complement C3 - analysis</subject><subject>Complement C4 - analysis</subject><subject>Female</subject><subject>Health technology assessment</subject><subject>Humans</subject><subject>Immunosorbent Techniques</subject><subject>Male</subject><subject>Middle Aged</subject><subject>Myasthenia Gravis - blood</subject><subject>Myasthenia Gravis - therapy</subject><issn>1473-0502</issn><issn>1878-1683</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2005</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNqFkE1LxDAQhoMorq7-BGVP3lqTNk3ak8jix8KCFz2HNJlglrapSbqw_94sW_DoaebwvDO8D0J3BOcEE_a4y6OXQ1A2LzCmOeY5JvQMXZGa1xlhdXmedsrLDFe4WKDrEHYYE04adokWpGooJaS4QsWm76fBSR2cH6N1wyp-g5fjYSUHvVKuHzvoYYgrqaLdyyNxgy6M7ALcznOJvl5fPtfv2fbjbbN-3maqZGXMQKmStJQzzWRroK0q3paM11xRUzRUGyONUbjFOvWBhulGVzIhvMVVUxdFuUQPp7ujdz8ThCh6GxR0nRzATUEw3qSyjCWwOoHKuxA8GDF620t_EASLoyyxE7MscZQlMBdJVsrdzw-mtgf9l5rtJODpBECqubfgRToBgwJtPagotLP_vPgFVSl-qw</recordid><startdate>20050601</startdate><enddate>20050601</enddate><creator>Pták, J.</creator><creator>Lochman, J.</creator><general>Elsevier Ltd</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope></search><sort><creationdate>20050601</creationdate><title>Immunoadsorption therapy and complement activation</title><author>Pták, J. ; Lochman, J.</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c363t-ecc31b476d6abfeb557b36787c4f294dffaffc0b0d101e96d9d5a7b37b0598223</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2005</creationdate><topic>Adult</topic><topic>Aged</topic><topic>Blood Component Removal</topic><topic>Complement Activation</topic><topic>Complement C3 - analysis</topic><topic>Complement C4 - analysis</topic><topic>Female</topic><topic>Health technology assessment</topic><topic>Humans</topic><topic>Immunosorbent Techniques</topic><topic>Male</topic><topic>Middle Aged</topic><topic>Myasthenia Gravis - blood</topic><topic>Myasthenia Gravis - therapy</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Pták, J.</creatorcontrib><creatorcontrib>Lochman, J.</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><jtitle>Transfusion and apheresis science</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Pták, J.</au><au>Lochman, J.</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Immunoadsorption therapy and complement activation</atitle><jtitle>Transfusion and apheresis science</jtitle><addtitle>Transfus Apher Sci</addtitle><date>2005-06-01</date><risdate>2005</risdate><volume>32</volume><issue>3</issue><spage>263</spage><epage>267</epage><pages>263-267</pages><issn>1473-0502</issn><eissn>1878-1683</eissn><abstract>Complement activation was studied in six patients treated with immunoadsorption columns Ig-ADSOPAK for myasthenia gravis. Mean therapy duration was 18.6 months (range 4–28 months). Prior and after each procedure, concentrations of C3 and C4 were examined, hemolytic activity of complement by a classic pathway (CH50) was determined, as well as terminal complement complex (TCC). After each immunoadsorption procedure, a decrease of C3 and C4 was noted (median 21.19% and 19.68%, respectively). The CH50 and TCC follow-up showed statistically significant complement activation. Median of TCC accrual was 60.21% and median of CH50 decrease was 23.24%. No clinical manifestations of complement activation were present. With increasing number of procedures a marked decrease of TCC activation was observed in five patients, which was statistically significant in three of them (
p
<
0.05). This finding may indicate an immunomodulating effect of long-term adsorption therapy. With increasing number of procedures, an inhibition in complement system reactivity occurs. This result, however, has to be confirmed on a larger group of patients.</abstract><cop>England</cop><pub>Elsevier Ltd</pub><pmid>15944112</pmid><doi>10.1016/j.transci.2004.07.014</doi><tpages>5</tpages></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 1473-0502 |
| ispartof | Transfusion and apheresis science, 2005-06, Vol.32 (3), p.263-267 |
| issn | 1473-0502 1878-1683 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_67918766 |
| source | MEDLINE; Elsevier ScienceDirect Journals |
| subjects | Adult Aged Blood Component Removal Complement Activation Complement C3 - analysis Complement C4 - analysis Female Health technology assessment Humans Immunosorbent Techniques Male Middle Aged Myasthenia Gravis - blood Myasthenia Gravis - therapy |
| title | Immunoadsorption therapy and complement activation |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-02-05T07%3A29%3A09IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Immunoadsorption%20therapy%20and%20complement%20activation&rft.jtitle=Transfusion%20and%20apheresis%20science&rft.au=Pt%C3%A1k,%20J.&rft.date=2005-06-01&rft.volume=32&rft.issue=3&rft.spage=263&rft.epage=267&rft.pages=263-267&rft.issn=1473-0502&rft.eissn=1878-1683&rft_id=info:doi/10.1016/j.transci.2004.07.014&rft_dat=%3Cproquest_cross%3E67918766%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=67918766&rft_id=info:pmid/15944112&rft_els_id=S1473050205000480&rfr_iscdi=true |